Soleno Therapeutics tumbles despite Q3 earnings, revenue beat
Investing.com - Piper Sandler has raised its price target on Alphatec Holdings (NASDAQ:ATEC) to $25.00 from $20.00 while maintaining its Overweight rating following the company’s better-than-expected third-quarter performance. The new target represents further upside potential despite ATEC’s impressive 108% return over the past year, according to InvestingPro data.
The medical device company reported Q3 results on October 30 that exceeded expectations across all key metrics, demonstrating continued market share gains in the spine surgery sector. This performance builds on ATEC’s robust 26.27% revenue growth over the last twelve months, with total revenue reaching $682.24 million.
Following the strong quarterly performance, Alphatec raised its full-year guidance beyond the magnitude of the Q3 beat, with the improvement driven entirely by its surgical business segment. While InvestingPro data shows the company is not yet profitable (with -$1.14 EPS), its strong financial health score of "GOOD" and current ratio of 2.88 indicate solid operational stability.
Piper Sandler identified several potential growth catalysts for Alphatec, including ongoing market disruption, the upcoming Valence product launch, and increased adoption of the company’s cervical and deformity portfolio.
The research firm noted that Alphatec management continues to prioritize profitable sales growth, which it believes should drive sustained value creation over the long term.
In other recent news, Alphatec Holdings reported impressive third-quarter 2025 earnings, with revenue reaching $197 million, marking a 30% increase compared to the previous year. The company also exceeded earnings per share (EPS) expectations, posting $0.03 against an anticipated loss of $0.04, resulting in a 175% surprise. Following these results, Canaccord Genuity raised its price target for Alphatec to $25 from $20, maintaining a Buy rating. The company’s surgical revenue grew by 31%, and its EOS imaging technology revenue increased by 29%. Additionally, Alphatec experienced nearly 30% growth in surgical volume and a 26% increase in new surgeon users. Established territories saw a 30% growth during the quarter. These developments highlight Alphatec’s strong performance and potential in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.